Medicines360 Names Jessica Grossman as CEO

Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the company has appointed Jessica Grossman, M.D., as its Chief Executive Officer, effective immediately. Dr. Grossman has been chair of the Board of Directors of Alliance Partners360, Medicines360’s for-profit subsidiary, since 2014 and a director of Medicines360 since 2011.

SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the company has appointed Jessica Grossman, M.D., as its Chief Executive Officer, effective immediately. Dr. Grossman has been chair of the Board of Directors of Alliance Partners360, Medicines360’s for-profit subsidiary, since 2014 and a director of Medicines360 since 2011.

“Jessica is a seasoned industry executive and medical technology pioneer with a proven track record at women’s health care companies. She brings a wealth of experience in product development and commercialization, coupled with the ability to move quickly and nimbly to accelerate product offerings,” said Dr. Victoria Hale, Founder and Board Member of Medicines360. “Her leadership, vision and entrepreneurial background will be invaluable assets to Medicines360 as the company transforms from development and commercialization of its first product and moves to the next chapter of expanded product growth and global leadership in women’s health.”

Dr. Grossman most recently served as president and CEO of Sense4Baby, Inc., a start-up company that developed an innovative, wireless maternal/fetal heart rate monitoring system for women with high-risk pregnancies. During her tenure, the company closed a $4 million Series A investment and she rapidly led the company to a successful acquisition following U.S. Food and Drug Administration (FDA) approval, CE mark and commercialization of the company’s lead product within 18 months of joining the organization. In addition, Dr. Grossman was founder and president of Gynesonics, an early-stage medical device company focused on minimally invasive solutions for women’s health. She raised more than $22 million in venture capital financing and invented and helped develop the first intrauterine, ultrasound-guided radiofrequency ablation device for fibroid tumors, a common disorder in women. Dr. Grossman was also a medical director at Ethicon Endo-Surgery, a part of the Johnson & Johnson family of companies.

“I am thrilled by the opportunity to take on this leadership role at Medicines360 at a pivotal time in the company’s evolution. As CEO, my top priorities will be building a robust pipeline of women’s health products and strengthening our partnership relationships for long-term sustainability,” said Dr. Grossman. “Medicines360 is a groundbreaking company seeking to expand access, educate and improve the lives of women in the U.S. and around the world. The company was founded by visionary Victoria Hale Ph.D., with a mission to provide all women with the ability to access and choose quality medicines, regardless of their socioeconomic status, insurance status, or geographic location. I am honored to follow Victoria and I share her commitment and passion for women’s health. I look forward to helping the company advance innovative medical solutions and a better future for all women, regardless of their insurance coverage or where they live.”

Dr. Grossman earned a Medical Degree from Thomas Jefferson University in Philadelphia and an undergraduate degree with honors from Brandeis University. She also has performed research at the Beth Israel Deaconess Medical Center, one of the teaching hospitals of Harvard Medical School.

About Medicines360

Medicines360, located in San Francisco, California, is an innovative nonprofit global women’s health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance status or geographic location. Medicines360 was founded in 2009 and introduced its first product, a progestin intrauterine device (IUD) in February 2015 with the goal of expanding access. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need.

For more information, visit www.medicines360.org.

 

Media Contact:

415-951-8700

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.